Esperite's (ESP) The Cell Factory received European funding to develop the 2nd generation EVs drug for treatment of Stroke
03. Mai 2018 05:36 ET
|
Esperite N.V.
Esperite's biotech company The Cell Factory, Belgium has received funding from the European Union's Horizon 2020 research and innovation Programme for development and characterization of the...
ESPERITE NV (ESP) delays publication of Annual Report 2017
30. April 2018 06:55 ET
|
Esperite N.V.
Amsterdam, The Netherlands - 30 April 2018 Esperite regrets to announce that due to technical issues and despite the constant efforts provided by the different teams involved, the publication of...
ESPERITE (ESP): EUR 1,200,000 of new funding provided by European Select Growth Opportunities Fund until May 25, 2018.
11. April 2018 01:17 ET
|
Esperite N.V.
Continuation of support to Esperite's strategy, commercial activities and development of innovative technologies in the field of genetics and regenerative medicines Amsterdam, The Netherlands -...
Esperite (ESP), The Cell Factory presents pre-clinical results on the new products of the 2nd generation EV's drugs for treatment of inflammatory diseases
29. März 2018 03:14 ET
|
Esperite N.V.
Esperite with its biotech company The Cell Factory has acquired from OPBG the full rights to the IP and the international patent family covering the invention and the therapeutic use of the EV's...
ESPERITE (ESP) : L1 Capital subscribes to the 16th tranche of investment today
02. März 2018 01:17 ET
|
Esperite N.V.
Amsterdam, The Netherlands - 2 March 2018 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today the 16th Tranche of EUR 250,000 is issued as a private placement of 25...
ESPERITE (ESP): EUR 500,000 of new funding provided by European Select Growth Opportunities Fund until March 2, 2018.
16. Februar 2018 01:17 ET
|
Esperite N.V.
Continuation of support to Esperite's strategy, commercial activities and development of innovative technologies in the field of genetics and regenerative medicines Amsterdam, The Netherlands -...
ESPERITE (ESP) and BGI Genomics (BGI) sign a strategic agreement to offer Whole Genome Sequencing on a large scale.
31. Januar 2018 07:26 ET
|
Esperite N.V.
Esperite with BGI sequencing technology will enable the global population easier access to the gold standard in clinical genetic testing. Amsterdam, The Netherlands - 31 January 2018 BGI is the...
ESPERITE (ESP) : L1 Capital subscribes to the 14th tranche of investment today
31. Januar 2018 01:17 ET
|
Esperite N.V.
Amsterdam, The Netherlands - 31 January 2018 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today the 14th Tranche of EUR 250,000 is issued as a private placement of 25...
ESPERITE (ESP) : L1 Capital subscribes to the 13th tranche of investment today
16. Januar 2018 01:17 ET
|
Esperite N.V.
Amsterdam, The Netherlands - 16 January 2018 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today the 13th Tranche of EUR 250,000 is issued as a private placement of 25...
ESPERITE (ESP) : transfers its laboratory activity to Geneva and consequently sells its Belgium loss making subsidiary and avoids EUR 4 millions of future cash out for charges and financial costs
10. Januar 2018 09:07 ET
|
Esperite N.V.
Amsterdam, The Netherlands - 10 January 2018 As Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") is completing its strategy to concentrate its laboratory activities in its...